Quantcast
Last updated on April 21, 2014 at 7:52 EDT

Latest Monoclonal antibody therapy Stories

2013-08-29 08:24:48

Proprietary PD-1 antibody to be combined with TIM-3 and LAG-3 antagonists SAN DIEGO, Aug. 29, 2013 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced the expansion of its proprietary immunotherapy antibody portfolio to include multiple new combination therapies. Using its SHM-XEL platform, the Company has recently developed a proprietary anti-PD-1 antibody, known as ANB011, with key differentiating advantages over...

2013-08-26 00:20:28

Common Stock Trading on Nasdaq OMX Stockholm Exchange and OTCQX Trading Platform TARRYTOWN, N.Y., Aug. 26, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (Nasdaq OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) (the "Company") announced today the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation. The merger combines Immune's antibody therapeutic platform focused on the treatment of inflammatory diseases and cancer with EpiCept's early stage cancer...

2013-08-20 08:29:59

Experienced Leader Brings Decades of Expertise in Development of Next-Generation Biologic Therapeutics SAN DIEGO, Aug. 20, 2013 /PRNewswire/ -- Ambrx today announced the appointment of Peter Kiener, Ph.D., as chief scientific officer. Dr. Kiener brings decades of expertise in the development of next-generation biologic therapeutics, including multi-specific, antibody based biologics while president, chief executive officer and cofounder of Zyngenia. "Dr. Kiener has an impressive...

2013-08-13 08:29:26

TSX: AMF TORONTO, Aug. 13, 2013 /CNW/ - Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the three months ended June 30, 2013. "Through strategic collaborations and partnerships as well as our own internal research efforts, we continue to advance our diagnostics and therapeutic antibody programs", said Dr. Robert Gundel, Amorfix President and...

2013-08-06 04:21:26

BREDA, The Netherlands, August 6, 2013 /PRNewswire/ -- Meeting The Increasing Demand For Technologies That Enable Antibody Product Differentiation arGEN-X, a clinical stage biopharmaceutical company specialized in the creation and development of highly differentiated human antibody therapeutics, today announces the signing of its second non-exclusive license agreement for its antibody half-life extension technology,...

2013-06-28 20:22:37

TSX: AMF TORONTO, June 28, 2013 /CNW/ - Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for year ended March 31, 2013. "We continue to advance our diagnostic and therapeutic antibody programs and have recently reached a number of critical milestones", said Dr. Robert Gundel, Amorfix President and Chief Executive Officer.  "On the cancer front,...

2013-06-28 08:23:41

Announcement marks a major milestone in a new era of lower-cost biologic therapies LEAMINGTON SPA, England, June 28, 2013 /PRNewswire/ -- Hospira (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending the European Commission (EC) approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory bowel...

2013-06-24 08:26:57

SAN DIEGO, June 24, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) announced today that preclinical data of its therapeutic fully human anti-PD-L1 and anti-PD-1 monoclonal antibodies (mAbs) will be presented at the IBC 8(th) Annual Next Generation Protein Therapeutics Summit, June 26( )- 28 in San Diego. In recent clinical studies,(([1])) immunomodulatory anti-PD-1 and anti-PD-L1 antibodies have shown great promise for the treatment of solid tumors. By...

2013-06-06 12:26:32

Paper demonstrates potential for cow antibodies to treat human diseases LA JOLLA, Calif., June 6, 2013 /PRNewswire/ -- Fabrus Inc., a company developing a next-generation antibody discovery platform that expands the therapeutic applications of antibodies, today announced the publication of data in the journal Cell detailing a structural and sequence analysis of unusually long CDR3 antibodies from cows. Fabrus scientists were co-authors on the paper detailing results of work led by...

2013-06-06 08:26:20

DUBLIN, June 6, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/272vtc/monoclonal ) has announced the addition of the "Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion" [http://www.researchandmarkets.com/research/272vtc/monoclonal ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )...